Sustained Response With Secukinumab in Axial Spondyloarthritis
Results showed that at Week 52, secukinumab was associated with a significant and clinically meaningful reduction in disease activity compared with placebo.
Spondyloarthritis
Incident Hypertension Associated With Continuous NSAID Use in Ankylosing Spondylitis
Researchers investigated the association of NSAID use with the development of incident hypertension in a cohort of patients with ankylosing spondylitis.
IL-41 Levels Elevated in Synovium of Patients With Psoriatic Arthritis
Researchers investigated the protein expression of interleukin (IL)-41 in the synovial tissue of patients with psoriatic arthritis, rheumatoid arthritis, and osteoarthritis and evaluated the production of IL-41 from the enthesis.
Increased Risk for Certain Inflammatory Diseases With Newly Diagnosed Ankylosing Spondylitis
Researchers investigated the risk for immune-mediated inflammatory diseases in patients with ankylosing spondylitis.
Reduced Mobility From Bone Bridge Formation Affects Low BMD in Ankylosing Spondylitis
Researchers conducted this study to determine whether bone bridge formation was correlated with low bone mineral density in patients with ankylosing spondylitis.
TNFi Therapy Affects Osteogenic Factors in Axial Spondyloarthritis
Researchers assessed serum levels of osteogenic factors and the different regulators of bone formation in patients with early axial spondyloarthritis.
Ankylosing Spondylitis Linked With High Prevalence of Depression
This study aimed to provide an estimate of depression prevalence among patients with ankylosing spondylitis vs those without ankylosing spondylitis.
Secukinumab Effective, Reduces Disease Activity in Patients With Axial Spondyloarthritis
A phase 3 trial evaluating the efficacy and safety of secukinumab in patients with non-radiographic axial spondyloarthritis (nr-axSpA) met its 16-week primary end point, according to Novartis.
Long-Term TNFi Therapy Outcomes in Psoriatic Arthritis
This study was conducted to describe patterns of first and subsequent TNFi use and response to long-term TNFi therapy in patients with PsA.
Guselkumab sBLA Submitted for Review of Psoriatic Arthritis Indication
Guselkumab (Tremfya) is already approved for moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
Next post in Psoriatic Arthritis
